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Abstract Pheochromocytoma is a neuroendocrine tumor characterized by the excessive 
production of catecholamines (epinephrine, norepinephrine, and dopamine). The diagnosis 
is suspected due to hypertensive paroxysms, associated with vegetative phenomena, due 
to the catecholaminergic hypersecretion. Diagnosis involves biochemical tests that reveal 
elevated levels of catecholamine metabolites (metanephrine and normetanephrine). 
Functional imaging, such as 123I-metaiodobenzylguanidine scintigraphy (123I-MIBG), 
has increased specificity in identifying the catecholamine-producing tumor and its 
metastases. The gold-standard treatment for patients with pheochromocytoma is 
represented by the surgical removal of the tumor. Before surgical resection, it is important 
to optimize blood pressure and intravascular volume in order to avoid negative 
hemodynamic events. 
Keywords  catecholamines, hypertensive paroxysm, metanephrine, normetanephrine, alpha-receptors 
blockade 
Highlights ✓ The gold-standard treatment in patients diagnosed with pheochromocytoma is the surgical 
removal of the tumor. Preoperative preparation is very important and its goal is to decrease 
the incidence of intraoperative cardiovascular complications. 
✓ The incidence of morbidity and mortality associated with the surgical removal of these 
tumors has decreased recently, considering the careful and prompt management in the 
perioperative period and the advancements of the surgical technique. 
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Introduction 
Pheochromocytoma is a neuroendocrine tumor derived 
from the chromaffin cells of the medullary portion of the 
adrenal glands, being characterized by the excessive 
production and release of catecholamines (adrenaline and 
noradrenaline) (1). Paraganglioma is also a catecholamine 
producing tumor, but with extra-adrenal localization (2). 
The most important clinical manifestation of 
pheochromocytoma is the hypertensive crisis due to the 
tumoral secretion of catecholamines (1). Surgical removal 
of the tumor represents the treatment of choice in order to 
cure and prevent cardiovascular complications (3). 
Discussions 
Epidemiology and etiology 
Pheochromocytoma occurs with equal frequency in 
men and women, and it can occur at any age (4).  In 20% 
of the cases, pheochromocytoma has a hereditary 
transmission, with bilateral localization (3). 10% of the 
cases of pheochromocytoma are malignant, and 
paraganglioma occurs in 10-15% of the cases (5). A genetic 
component has been identified in 30% of the cases of 
pheochromocytoma, being associated with Von Hippel-
Lindau disease, with neurofibromatosis, and with multiple 
endocrine neoplasia type 1 and type II syndrome (MEN I 
and MEN II) (6). The etiology of pheochromocytoma is 
represented by increased tumoral production and the 
secretion of catecholamines (4).  
Pathophysiology 
The pathophysiological mechanism underlying 
pheochromocytoma is represented by the increased release 
of catecholamine hormones, secreted by the tumor, 
continuously or in an episodic manner. These hormones, 
which include epinephrine, norepinephrine, and dopamine, 
excessively stimulate alpha- and beta-adrenergic receptors, 
with all the clinical manifestations in pheochromocytoma 
being related to this (7). 
The symptomatology in pheochromocytoma is given 
by the predominant type of catecholaminergic secretion. 
Epinephrine stimulates beta-1 and beta-2 adrenergic 
receptors. By stimulating beta-2 adrenergic receptors, 
epinephrine causes vasodilation in striate muscles. Also, 
epinephrine has metabolic effects, stimulating hepatic 
glycogenolysis and gluconeogenesis, thus leading to 
hyperglycemia (8). Norepinephrine stimulates alpha-1, 
alpha-2, and beta-2 adrenergic receptors, leading to 
vasoconstriction and increased blood pressure. 
Epinephrine and norepinephrine have positive 
chronotropic effects through their action on beta-1 
adrenergic receptors (9). Dopamine stimulates 
dopaminergic receptors D1 and D2. In cases of 
pheochromocytoma, dopamine concentrations are 
elevated, thus causing vasoconstriction and increased heart 
rate (10). Moreover, pheochromocytoma is characterized 
by the release of other substances, such as neuron-specific 
enolase, vasoactive intestinal peptide, or 
adrenocorticotropic hormone (ACTH), which cause 
various other clinical manifestations (9). 
Clinical presentation 
The classical manifestation in pheochromocytoma is 
represented by the hypertensive crisis, associated with 
palpitations and diaphoresis, these symptoms being the 
result of the massive release of catecholaminergic 
hormones from the tumor. This symptomatology is present 
in 40% of the patients with pheochromocytoma (11). The 
hypertensive paroxysm can be triggered by different type 
of stress, such as surgery or anesthetics, intense physical 
effort, smoking, or palpation of the lumbar region (12). 
The hypertensive crisis may last from a few minutes to 
a few hours. The end of the hypertensive paroxysm is 
characterized by arterial hypotension.  The crisis is also 
associated with various symptoms, such as headache, 
diaphoresis, and heart rhythm disorders, these 
manifestations supporting the positive diagnosis of 
pheochromocytoma. Also, anxiety, visual disturbances, 
nausea, chest pain, or abdominal pain are associated with 
hypertensive paroxysm (13). 
The effects of severe hypertension are quantified in 
lesions of the end-organs, especially the heart, kidney, 
eyes, and central nervous system. Also, hypertensive 
paroxysm can be associated with the signs and symptoms 
of hypertensive encephalopathy (such as an altered state of 
consciousness and convulsions) and acute myocardial 
ischemia due to the increased oxygen demand (14). Other 
clinical manifestations occur in pheochromocytoma due to 
the release of neuropeptides. Thus, the hypersecretion of 
ACTH leads to the occurrence of the signs and symptoms 
of hypercorticism. Also, the hypersecretion of calcitonin 
leads to hypocalcemia (15). Pheochromocytoma in genetic 
syndromes can be associated with other clinical signs, such 
as café-au-lait skin spots (13). 
Diagnosis 
When pheochromocytoma is suspected, the levels of 
catecholamines and their metabolites should be tested, such 
as metanephrines and normetanephrines. A rise in the 
plasma levels of metanephrines is an indicator of increased 
tumoral production and release of catecholamines.  This 
diagnostic test has both high sensitivity and specificity. 
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Measurement of urinary metanephrines is also a test with 
high sensitivity in the diagnosis of pheochromocytoma 
(16). The measurement of plasmatic and urinary 
vanillylmandelic acid (VMA) is a test used for the 
diagnosis of these tumors (15).  
Methoxytyramine is a marker used in the identification 
of malignant forms of pheochromocytoma. Also, 
chromogranin A is a marker of the presence of 
neuroendocrine tumors (17). The imaging evaluation 
(computed tomography [CT] and magnetic resonance 
imaging [MRI]) is important in establishing the 
localization and the dimensions of the tumor and also in 
identifying metastatic lesions. MRI describes the 
anatomical details and the vascular structures more clearly, 
but it does not identify small dimension tumors (18). 
Functional imaging using radiotracers such as 123I-
metaiodobenzylguanidine scintigraphy (123I-MIBG) and 
111In-DTPA-pentetreotide scintigraphy has increased 
specificity in identifying the catecholamine-producing 
tumors and their metastases (19). Also, genetic tests are 
required in patients with a family history of 
pheochromocytoma (17). 
Preoperative preparation 
Pheochromocytoma is associated with end-organ 
lesions as a result of the excess of catecholamines. In this 
context, the surgical removal of these tumors is 
recommended in order to cure and prevent the lesions. Chai 
et al. observed that in patients diagnosed with 
pheochromocytoma, open transperitoneal adrenalectomy is 
the gold standard treatment (18). Nevertheless, due to the 
constant technological developments and also the need for 
less invasive surgery, the laparoscopic approach has 
become more popular over time. Before surgical resection, 
it is important to optimize the blood pressure and the 
intravascular volume as steps to avoid the negative 
hemodynamic events during surgery (20). 
The need for preoperative antihypertensive therapy has 
been studied in patients with pheochromocytoma (21). In a 
retrospective study by Pogorzelski et al. from 2006 – 2012 
that included 67 patients diagnosed with 
pheochromocytoma, a regression of arterial hypertension 
after surgical treatment of the tumor was noticed (22). 
Recent evidence shows that preoperative preparation with 
antihypertensive therapy decreases intra- and postoperative 
cardiovascular complications (23). The Endocrine Society 
Clinical Guidelines Subcommittee recommends 
preoperative alpha-blockade in patients undergoing the 
resection of the pheochromocytoma (22).  
Guidelines indicate that preoperative preparation for 
the surgical removal of pheochromocytoma requires 5-15 
days of the administration of alpha-receptor blockers and 
methods to increase the intravascular volume (20). The 
purpose of the preoperative preparation is to control the 
blood pressure for at least 3-5 days, with a systolic blood 
pressure under 130 mmHg and a diastolic value under 80 
mmHg24. 
The main cause of hypertension in patients with 
pheochromocytoma is the alpha-receptor activation due to 
the excess of catecholamines. In this context, the first line 
therapy is represented by alpha-receptor antagonists. Also, 
beta-receptor antagonists and calcium channel blockers are 
used (25). 
Prazosin, doxazosin, and terazosin are selective alpha-
1 receptor antagonists. These drugs act on the alpha-1 
receptors and produce vasodilation. The antagonism 
produced by these drugs is reversible (24). Prazosin is most 
frequently used in patients with indications of surgical 
resection of pheochromocytoma. Doses of prazosin are 
gradually increased, depending on the hypotensive 
response of the patient. Studies revealed a good 
perioperative control and adequate alpha-blockade in 
patients with pheochromocytoma (26). Doxazosin and 
terazosin are alternatives to prazosin, which is most 
commonly used. 
Beta-blockers should not be administered before the 
initiation of alpha-receptor antagonists because the 
antagonism of beta-receptors can lead to acute cardiac 
failure and pulmonary edema. Beta-blockers are 
administered only after the initiation of alpha-receptor 
blockers (22). Cardio selective beta-blockers are more 
frequently used because this class has fewer side-effects. 
The most commonly used beta-receptor antagonists in 
patients with pheochromocytoma with indication for 
resection are metoprolol, atenolol, bisoprolol, carvedilol, 
propranolol (which is a non-selective beta-blocker), and 
labetalol. Labetalol has effects of alpha- and beta-receptor 
antagonism (27).  
Calcium channel blockers can be administered as 
primary drugs in order to control hypertension or as adjunct 
antihypertensive therapy. Guidelines recommend these 
drugs especially for the control of blood pressure in 
patients with hypertensive paroxysms (23). The most 
commonly used calcium channel blockers are amlodipine, 
nicardipine, nifedipine, verapamil, and diltiazem (28).  
Goldstein et al. highlighted the importance of alpha-
blockade in patients diagnosed with pheochromocytoma 
with indication for the surgical removal of the tumor. They 
found 69% of the patients without alpha-blockade 
experienced perioperative cardiovascular complications, 
compared to 3% of the patients who received alpha-
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blockers and did not experience intraoperative 
cardiovascular complications (26). Because the 
administration of alpha-receptor blockers can cause severe 
orthostatic hypotension, increasing intravascular volume 
with intravenous crystalloids and colloids is recommended 
(25). 
Intraoperative drugs used in cases of hypertensive 
paroxysm are sodium nitroprusside and nitroglycerine 
(28). Also, esmolol is a beta-receptor blocker used 
intraoperatively to control hypertension and tachycardia 
(29). Intraoperative hypertension and hemodynamic 
instability occur depending on anesthetic drugs, tumoral 
dimensions, and plasma catecholamine levels (30).  
Many studies report that postoperative hypotension has 
an incidence of 20-70% and is associated with the 
administration of the alpha-receptor antagonists before 
surgery and hypotensive agents administered during the 
surgical intervention (31, 32). Also, hyperinsulinemia and 
hypoglycemia may be noticed after the removal of the 
tumor. 
After the surgical resection of the tumor, the values of 
blood pressure will normalize. Also, the values of the 
catecholamine metabolites will be within normal limits. 
Guidelines recommend that postoperative follow-up 
should occur through a three-month assessment period 
(33). 
Conclusions 
The clinical manifestations of pheochromocytoma may 
vary. The classical manifestation is represented by 
hypertensive paroxysm, associated with a vegetative 
phenomenon, such as palpitations or diaphoresis. CT scans 
represent the best functional imaging tests. Also, MRI 
scans may be used in cases of metastases or when radiation 
is to be avoided.  
The gold-standard treatment in patients diagnosed with 
pheochromocytoma is the surgical removal of the tumor. 
Preoperative preparation is very important and its goal is to 
decrease the incidence of intraoperative cardiovascular 
complications. The first-line treatment is represented by 
alpha-receptor antagonists, especially selective ones 
(alpha-1 receptor antagonists). Also, beta-receptor 
antagonists and calcium channel blockers are used as 
adjunct antihypertensive therapy. The vascular volume 
replacement with fluids administered intravenously is 
recommended to avoid hypotension, which is the most 
common complication after tumor removal. The incidence 
of morbidity and mortality associated with the surgical 
removal of these tumors has decreased recently, 
considering the careful and prompt management in the 
perioperative period and the advancements of the surgical 
technique. 
Acknowledgements 
All authors have contributed equally to this paper. 
Conflict of interest disclosure 
There are no known conflicts of interest in the 
publication of this article. The manuscript was read and 
approved by all authors. 
Compliance with ethical standards 
Any aspect of the work covered in this manuscript has 
been conducted with the ethical approval of all relevant 
bodies and that such approvals are acknowledged within 
the manuscript. 
References 
1. Pacak K. Preoperative management of the 
pheochromocytoma patient. J Clin Endocrinol Metab. 
2007; 92(11): 4069–79. 
2. Lloyd RV, Tischer AS, Kimura N, et al. Adrenal 
tumors: introduction. World Health Organization 
Classification of Tumours: pathology and genetics of 
tumours of endocrine organs. Lyon, France: IARC 
Press, 2004; 136-138. 
3. Barakat MT, Meeran K, Bloom SR. Neuroendocrine 
tumours. Endocr Relat Cancer. 2004; 11(1): 1–18. 
4. Elder EE, Elder G, Larsson C. Phaeochromocytoma 
and functional paraganglioma syndrome: no longer the 
10% tumor. J Surg Oncol. 2005; 89(3): 193-201. 
5. Rashmi R, Rewari V. Current perioperative 
management of pheochromocytomas. Indian J Urol. 
2017; 33(1): 19–25. 
6. Gimenez-Roqueplo AP, Dahia PL, Robledo M. An 
update on the genetics of paraganglioma, 
phaeochromocytoma and associated hereditary 
syndromes. Hormone and Metabolic Res. 2012; 44(5): 
328-333. 
7. Lehnert H. Pheochromocytoma. Pathophysiology and 
clinical management. Karger Basel, 2004. 
8. Pacak K, Koch CA, Wofford MR, Ayala AR. In: 
Overview of endocrine hypertension. Endotext. De 
Groot LJ, Beck-Peccoz P, Chrousos G, Dungan K, 
Grossman A, Hershman JM, et al., editors. South 
Dartmouth, MA: MDText.com, Inc; 2000. 
Pheochromocytoma –manifestations, diagnosis and perioperative management 
 247 
9. Dahia PL. Pheochromocytoma and paraganglioma 
pathogenesis: Learning from genetic heterogeneity. Nat 
Rev Cancer. 2014; 14(2): 108–19.  
10. Bravo E, Tagle R. Phaeochromocytoma: state-of-the-
art and future prospects. Endocrine Reviews. 2003; 
24(4): 593-53. 
11. Galetta F, Franzoni F, Bernini G, et al. Cardiovascular 
complications in patients with pheochromocytoma: a 
mini-review. Biomed Pharmacotherapy. 2010; 64(7): 
505-9. 
12. Lenders JW, Duh QY, Eisenhofer G, et al. 
Pheochromocytoma and paraganglioma: An endocrine 
society clinical practice guideline. J Clin Endocrinol 
Metab. 2014; 99(6): 1915–42. 
13. Lenders JW, Eisenhofer G, Mannelli M, Pacak K. 
Phaeochromocytoma. Lancet. 2005; 366(9486): 665–
75. 
14. Samuel MZ, Vitaly Kantorovich, Karel Pacak. 
Hypertension in pheochromocytoma: characteristics 
and treatment. Endocrinol Metab Clin North Am. 2011; 
40(2): 295-311. 
15. Kizer JR, Koniaris LS, Edelman JD, et al. 
Pheochromocytoma crisis, cardiomiopathy and 
hemodynamic collapse. Chest. 2000; 118(4): 1221-3. 
16. Lenders JW, Pacak K, Walther MM, et al. Biochemical 
diagnosis of pheochromocytoma: Which test is best? 
JAMA. 2002; 287(11): 1427–34. 
17. Eisenhofer G. Screening for pheochromocytomas and 
paragangliomas. Curr Hypertens Rep. 2012; 14(2): 
130–7. 
18. Timmers HJ, Taieb D, Pacak K. Current and future 
anatomical and functional imaging approaches to 
pheochromocytoma and paraganglioma. Horm Metab 
Res. 2012; 44(5): 367–72. 
19. Martucci I, Pacak K. Pheochromocytoma and 
paraganglioma: diagnosis, genetics, management and 
treatment. Curr Probl Cancer. 2014; 38(1): 7-41. 
20. Lentschener C, Gaujoux S, Tesniere A, Dousset B. 
Point of controversy: perioperative care of patients 
undergoing pheochromocytoma removal-time for a 
reappraisal? Eur J Endocrinol. 2011; 165(3): 365–73. 
21. Baguet JP, Hammer L, Mazzuco TL, et al. 
Circumstances of discovery of phaeochromocytoma: A 
retrospective study of 41 consecutive patients. Eur J 
Endocrinol. 2004; 150(5): 681–6.  
22. Eisenhofer G, Bornstein SR, Brouwers FM, et al. 
Malignant pheochromocytoma: Current status and 
initiatives for future progress. Endocr Relat Cancer. 
2004; 11(3): 423–36. 
23. Tauzin-Fin P, Sesay M, Gosse P, Ballanger P. Effects 
of perioperative alpha1 block on haemodynamic 
control during laparoscopic surgery for 
phaeochromocytoma. Br J Anaesth. 2004; 92(4): 512–
7. 
24. Zelinka T, Strauch B, Petrak O, et al. Increased blood 
pressure variability in pheochromocytoma compared to 
essential hypertension patients. Journal of 
Hypertension. 2005; 23(11): 2033-9. 
25. Prys-Roberts C, Farndon JR. Efficacy and safety of 
doxazosin for perioperative management of patients 
with pheochromocytoma. World J Surg. 2002; 26(8): 
1037-1042. 
26. James M. The impact of changes in drug availability for 
hemodynamic management in pheochromocytoma: 
Prêt-à-porter or tailor-made? Can J Anaesth. 2015; 
62(12): 1244–7. 
27. Shao Y, Chen R, Shen ZJ, et al. Preoperative alpha 
blockade for normotensive pheochromocytoma: Is it 
necessary? J Hypertens. 2011; 29(12): 2429–32. 
28. Agrawal R, Mishra SK, Bhatia E, et al. Prospective 
study to compare peri-operative hemodynamic 
alterations following preparation for 
pheochromocytoma surgery by phenoxybenzamine or 
prazosin. World J Surg. 2014; 38(3): 716–23. 
29. Hariskov S, Schumann R. Intraoperative management 
of patients with incidental catecholamine producing 
tumors: A literature review and analysis. J Anaesthesiol 
Clin Pharmacol. 2013; 29(1): 41–6.  
30. Bénay CE, Tahiri M, Lee L, et al. Selective strategy for 
intensive monitoring after pheochromocytoma 
resection. Surgery. 2016; 159(1): 275–82. 
31. Scholten A, Vriens MR, Cromheecke GJ, Borel Rinkes 
IH, Valk GD. Hemodynamic instability during 
resection of pheochromocytoma in MEN versus non-
MEN patients. Eur J Endocrinol. 2011; 165(1): 91–6. 
32. Namekawa T, Utsumi T, Kawamura K, et al. Clinical 
predictors of prolonged postresection hypotension after 
laparoscopic adrenalectomy for pheochromocytoma. 
Surgery. 2016; 159(3): 763–70. 
33. Petrak O, Strauch B, Zelinka T, et al. Factors 
influencing arterial stifness in pheochromocytoma and 
effect of adrenalectomy. Hypertens Res. 2010; 33(5): 
454-459. 
